Synlogic to Present at the Jefferies Global Healthcare Conference
May 23 2023 - 6:50AM
Synlogic, Inc. (Nasdaq: SYBX), the leading company advancing
therapeutics based on synthetic biology, today announced that Aoife
Brennan, M.B. Ch.B., President and Chief Executive Officer,
will present at the Jefferies Global Healthcare Conference being
held in New York, NY, June 7-9, 2023.
Presentation Details:
- Wednesday, June 7, 2023
- 2:00-2:25 PM EDT (Track 2)
- To access the webcast of the presentation, please click
here
A replay of the presentation will be available for 90 days.
Recorded presentations, if available, can be found on
the Archived Events section of the Synlogic website.
About Synlogic
Synlogic is the leading company advancing therapeutics based on
synthetic biology. Synlogic’s pipeline includes its lead program in
phenylketonuria (PKU), which has demonstrated proof of concept with
plans to start a pivotal, Phase 3 study in the first half of 2023,
and additional novel drug candidates designed to treat
homocystinuria (HCU), enteric hyperoxaluria and gout. The rapid
advancement of these potential biotherapeutics, called Synthetic
Biotics, has been enabled by Synlogic’s reproducible,
target-specific drug design. Synlogic uses programmable,
precision genetic engineering of well-characterized probiotics to
exert localized activity for therapeutic benefit, with a focus on
metabolic and immunological diseases. In addition to its clinical
programs, Synlogic has a research collaboration with
Roche on the discovery of a novel Synthetic Biotic for the
treatment of inflammatory bowel disease or IBD. Synlogic has also
developed two drug candidates through a research collaboration with
Ginkgo Bioworks: SYNB1353, designed to consume methionine for the
potential treatment of HCU, and SYNB2081, designed to lower uric
acid for the potential treatment of gout. For additional
information visit www.synlogictx.com.
Forward-Looking Statements
This press release contains "forward-looking statements" that
involve substantial risks and uncertainties for purposes of the
safe harbor provided by the Private Securities Litigation Reform
Act of 1995. All statements, other than statements of historical
facts, included in this press release regarding strategy, future
operations, clinical development plans, future financial position,
future revenue, projected expenses, prospects, plans and objectives
of management are forward-looking statements. In addition, when or
if used in this press release, the words "may," "could," "should,"
"anticipate," "believe," “look forward,” "estimate," "expect,"
"intend," on track,” "plan," "predict," “prepare” and similar
expressions and their variants, as they relate to Synlogic,
may identify forward-looking statements. Examples of
forward-looking statements, include, but are not limited to,
statements regarding the potential of Synlogic's approach
to Synthetic Biotics to develop therapeutics to address a wide
range of diseases including: inborn errors of metabolism and
inflammatory and immune disorders; our expectations about
sufficiency of our existing cash balance; the future clinical
development of Synthetic Biotics; the
approach Synlogic is taking to discover and develop novel
therapeutics using synthetic biology; and the expected timing
of Synlogic's clinical trials of SYNB1934, SYNB1353,
SYNB8802 and SYNB2081 and availability of clinical trial data.
Actual results could differ materially from those contained in any
forward-looking statements as a result of various factors,
including: the uncertainties inherent in the clinical and
preclinical development process; the ability
of Synlogic to protect its intellectual property rights;
and legislative, regulatory, political and economic developments,
as well as those risks identified under the heading "Risk Factors"
in Synlogic's filings with the U.S. Securities and
Exchange Commission. The forward-looking statements contained in
this press release reflect Synlogic's current views with
respect to future events. Synlogic anticipates that
subsequent events and developments will cause its views to change.
However, while Synlogic may elect to update these
forward-looking statements in the
future, Synlogic specifically disclaims any obligation to
do so. These forward-looking statements should not be relied upon
as representing Synlogic's view as of any date subsequent
to the date hereof.
Media Contact: media@synlogictx.com
Investor Relations: investor@synlogictx.com
Synlogic (NASDAQ:SYBX)
Historical Stock Chart
From Aug 2024 to Sep 2024
Synlogic (NASDAQ:SYBX)
Historical Stock Chart
From Sep 2023 to Sep 2024